Offer extended until 31 July 2026: get a 10% early-bird discount on all events starting on or after 25 August 2026. To the promotion
GMP search engine – look up GMP compliance regulations and news
Bio Assays - Commentary – First Supplement to USP 35-NF 30
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
Amongst others, the USP published the received comments and responses to General Chapter/Section: <1032> Design and Development of Biological Assays in the Commentary – First Supplement to USP 35-NF 30.
The USP received 13 comments to different parts of this chapter. Comments to the following topics are included:
- Necessary Harmonization with compendial references e.g. European Pharmacopoiea
- Helpful case study examples that illustrate the application
- The need that the assay acheive a specific observable response
- Assessment of similarity using the entire concentration-response curve, including the asymptotes.
- Potency assay for assessment of stability
- Need of documenting the source of assay's cell line
The complete comments can be found at Commentary – First Supplement to USP 35-NF 30.
In this respect you may also want to pay attention to ECA's New Education Course on "Bioassays, and Bioanalytics" from 27-28 March 2012 in Copenhagen, Denmark.
Author:
Axel H. Schroeder
CONCEPT HEIDELBERG (a service provider entrusted by the ECA Foundation)
Related GMP News
01.07.2026Several FDA Warning Letters and Untitled Letters on Asbestos Testing of Talc in OTC Drug Products
24.06.2026Analytical Quality Group Developments January through April 2026
17.06.2026BioPhorum Publishes a Roadmap for QC Sample Test Execution
03.06.2026EMA Provides an Outlook on the Product-Specific Bioequivalence Guidelines Expected in 2026
03.06.2026FDA Warning Letter: Missing Method Validation - From a QC Topic to a Market-Access Problem
28.05.2026WHO Working Document on Bioequivalence open for Public Consultation